(VIANEWS) – The Market ended the session with NANOBIOTIX (NANO.PA) rising 13.53% to €8.56 on Monday while CAC 40 dropped 0.07% to €7,427.31.
NANOBIOTIX’s last close was €7.54, 0.79% under its 52-week high of €7.60.
About NANOBIOTIX
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.
Earnings Per Share
As for profitability, NANOBIOTIX has a trailing twelve months EPS of €-1.74.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NANOBIOTIX’s stock is considered to be oversold (<=20).
Volatility
NANOBIOTIX’s last week, last month’s, and last quarter’s current intraday variation average was 6.17%, 2.29%, and 5.53%.
NANOBIOTIX’s highest amplitude of average volatility was 6.17% (last week), 5.61% (last month), and 5.53% (last quarter).
Revenue Growth
Year-on-year quarterly revenue growth grew by 159.6%, now sitting on 4.78M for the twelve trailing months.
Moving Average
NANOBIOTIX’s value is way above its 50-day moving average of €5.01 and way above its 200-day moving average of €3.95.
More news about NANOBIOTIX (NANO.PA).
